Carrico Thomas Joeseph has made a notable move by acquiring 328 shares of Neuraxis, Inc. on October 8, 2026. This transaction is significant as it indicates Carrico’s ongoing confidence in the company and the broader electromedical industry.
Neuraxis, Inc., which operates under the Central Index Key (CIK) 0001933567, is categorized under the SIC code for electromedical and electrotherapeutic apparatus. The company is based in Carmel, Indiana, and has been actively involved in the development of innovative medical technologies.
According to the recent SEC filing, Carrico's acquisition was executed at a price of $4.84 per share. Following this transaction, Carrico now holds a total of 199,673 shares in Neuraxis. The filing stated, "Transaction Code: P" indicating a purchase transaction.
This acquisition may have implications for Neuraxis as it showcases insider confidence, which can influence investor sentiment and market perception. Additionally, it highlights the active engagement of company officers in the stock, potentially attracting further interest from other investors.
The filing does not specify what actions may follow this acquisition, leaving the future steps unclear. However, it marks an important moment for Carrico and Neuraxis as they continue to navigate the evolving landscape of the electromedical sector.
Details of the Transaction
The SEC filing indicates that Carrico Thomas Joeseph is an officer of Neuraxis, holding the titles of Chief Revenue Officer (CRO), Chief Commercial Officer (CCO), and Chief Product Officer (CPO). This multifaceted role suggests a deep involvement in the company's strategic direction and operational execution.
Furthermore, the transaction was classified under the SEC's Form 4, which is used to report the acquisition or disposition of securities by officers, directors, and beneficial owners. The filing confirms that the shares were acquired directly, denoted by the 'D' in the ownership nature section.
Company Information
Neuraxis, Inc. is incorporated in Delaware and operates within the electromedical and electrotherapeutic apparatus industry, as indicated by its SIC code 3845. The company has a fiscal year-end of December 31, which may be relevant for investors tracking its financial performance.
The filing also notes the business address of Neuraxis as 11611 N. Meridian St, Suite 330, Carmel, IN 46032, along with a business phone number of (812) 689-0791.
While the filing provides a comprehensive overview of the transaction and Carrico's role, it does not include any information regarding future plans for the shares acquired or any potential impact on Neuraxis's strategic initiatives.